Avantor, Inc. reported net sales of $1.66 billion for the fourth quarter of 2025, a 1% decrease compared to the fourth quarter of 2024, with an organic sales decline of 4%. Net income decreased significantly to $52 million from $500 million in the prior year, while adjusted EPS was $0.22. The company is undergoing a 'Revival program' to improve agility and drive top-line growth.

Avantor experienced a challenging third quarter in 2025, with net sales decreasing by 5% to $1.62 billion. The company reported a substantial net loss of $712 million, primarily driven by a $785 million non-cash goodwill impairment charge related to its Distribution reporting unit. Despite the loss, adjusted EPS was $0.22, and the company generated $207 million in operating cash flow.

Avantor's second quarter 2025 performance showed a slight decrease in net sales, reaching $1.68 billion, though organic revenue remained flat. Net income fell to $64.7 million, and adjusted EPS was $0.24. The Laboratory Solutions segment experienced a reported decrease in sales, while Bioscience Production saw an increase. The company generated strong operating cash flow of $154.4 million and free cash flow of $125.4 million.

Avantor's Q1 2025 revenue declined by 6% year-over-year, yet the company posted increased net income and maintained stable operating income. It also boosted its cost transformation target to $400 million to enhance future profitability.

Avantor reported Q4 2024 net sales of $1.69 billion, a 2% decrease YoY. However, organic growth was 1%. Net income surged to $500.4 million, and adjusted EBITDA was $307.7 million. Diluted GAAP EPS was $0.73, while adjusted EPS stood at $0.27. Free cash flow improved to $222.1 million.

Avantor reported a slight decrease in net sales but demonstrated strength in bioprocessing and laboratory solutions. The company is raising its free cash flow guidance for the year, driven by a disciplined approach to working capital and cost transformation programs running ahead of plan.

Avantor reported Q2 2024 results with net sales of $1.70 billion, a decrease of 2.4%. Net income increased to $93 million, and adjusted EBITDA was $306 million. Diluted GAAP EPS was $0.14, while adjusted EPS was $0.25. The company reaffirmed its fiscal year 2024 guidance.

Avantor's Q1 2024 results showed a decrease in net sales by 5.6% to $1.68 billion, with an organic decline of 6.3%. Despite the revenue decrease, the company saw outperformance in margins and profitability, with an adjusted EBITDA of $283 million and adjusted EPS of $0.22. The company reaffirmed its fiscal year 2024 guidance.

Avantor's Q4 2023 results showed a decrease in net sales by 4.0% to $1.72 billion, with a core organic decline of 4.8%. Net income decreased to $98.5 million, but adjusted EBITDA was $302.1 million. Diluted GAAP EPS was $0.15, while adjusted EPS was $0.25. The company's free cash flow for the year exceeded the top end of the guidance range.

Avantor reported Q3 2023 results, with net sales of $1.72 billion, a decrease of 7.3%. Core organic sales declined by 7.9%. Net income was $108.4 million, and Adjusted EBITDA was $317.8 million. Diluted GAAP EPS was $0.16, while adjusted EPS was $0.25. Operating cash flow was $230.7 million, and free cash flow was $193.0 million.

Avantor reported a decrease in net sales by 8.7% to $1.74 billion, with a core organic decline of 6.5%. Net income was ($7.3) million, while adjusted EBITDA reached $343.0 million. The company's diluted GAAP EPS was ($0.01), and adjusted EPS was $0.28. Operating cash flow was $168.2 million, and free cash flow was $138.1 million.

Avantor reported a decrease in net sales by 8.7% to $1.78 billion, with a core organic decline of 1.8%. Net income decreased to $121.5 million, and adjusted EBITDA was $346.2 million. Diluted GAAP EPS was $0.18, while adjusted EPS was $0.29.

Avantor's fourth quarter results met expectations, demonstrating core organic growth across all regions and strong margin expansion despite macroeconomic pressures. Full-year results reflected the strength of the core business, with 6% core organic growth in bioproduction, adjusted EBITDA margin expansion, and a double-digit increase in adjusted net income.

Avantor reported a 1.2% increase in net sales to $1.86 billion, with core organic growth of 7.8%. Adjusted EBITDA increased by 6.9% to $384.0 million, and adjusted EPS was $0.34. The company has updated its full-year guidance to reflect its third quarter performance, $400 million of revenue from its 2021 acquisitions, changes to foreign exchange rates and current market conditions. They now expect to deliver 2.5% - 3.0% organic growth (6.0% - 6.5% excluding COVID-19 headwinds) and $1.38 to $1.40 of adjusted EPS for the full year.

Avantor reported a 2.8% increase in net sales, reaching $1.91 billion. Core organic net sales grew by 6.4%. Net income increased to $187.4 million, and Adjusted EBITDA rose to $404.1 million. Diluted GAAP EPS was $0.28, with adjusted EPS at $0.37.

Avantor reported a strong first quarter in 2022, with net sales of $1.95 billion, a 9.2% increase compared to the first quarter of 2021. Organic net sales growth was 5.1%. Net income increased to $190.4 million, and Adjusted EBITDA increased 16.5% to $423.1 million.

Avantor's Q4 2021 net sales increased by 6.5% to $1.91 billion, with organic net sales growth of 2.5%. Net income rose to $94.0 million, and adjusted EBITDA increased by 15.6% to $369.8 million. Diluted GAAP EPS was $0.13, while adjusted EPS reached $0.36.

Avantor reported strong third-quarter results with net sales of $1.83 billion, a 14.3% increase compared to the third quarter of 2020. Net income increased to $156.8 million, and adjusted EBITDA increased 25.8% to $359.2 million.

Avantor reported net sales of $1.86 billion, a 25.7% increase, with organic net sales growth of 20.5%. Net income increased to $157.8 million, and adjusted EBITDA rose to $366.6 million. The company raised its full-year guidance, reflecting confidence in continued growth.

Avantor reported strong first quarter results with a 17.5% increase in revenue to $1.79 billion and a 248.9% increase in net income to $164.0 million. Adjusted EBITDA increased 38.2% to $363.1 million. The company is on track to achieve its free cash flow guidance of over $800 million for the full year.

Avantor reported a strong Q4 2020 with a 17.5% increase in revenue to $1.791 billion and organic revenue growth of 14.9%. Adjusted EBITDA increased by approximately 21% to $319.9 million, with an adjusted EPS growth of 57.2% to $0.29. Free cash flow was $286 million, a growth of 282%.

Avantor reported a 6.7% increase in revenue to $1.605 billion, with organic growth of 5.4%. Adjusted EBITDA increased by 14% to $285.6 million, and adjusted EPS rose by 63% to $0.24. The company experienced a net loss of $42.2 million, impacted by a loss on debt extinguishment.

Avantor reported Q2 2020 results with revenue of $1.48 billion, a 3.5% decline. Net income increased to $60.2 million, and adjusted EPS increased 32.5% to $0.19. The company achieved Adjusted EBITDA growth and strong cash generation despite a modest organic revenue decline. They also refinanced $2B unsecured notes lowering associated interest payments by 50%.

Avantor reported a revenue increase of 2.6% to $1.52 billion, with organic growth of 4.1%. Net income increased to $47 million, and adjusted EBITDA grew by 6% to $262.8 million. Adjusted EPS increased by 64% to $0.17, and free cash flow was $240.5 million, a 284% increase. The company withdrew its previously issued guidance due to COVID-19.

Avantor's Q4 2019 results showed strong sales, particularly in the biopharma business, margin expansion, and robust cash flow generation. Net sales increased by 3.4% to $1.52 billion, net income increased to $70.6 million, and adjusted EPS increased 89.9% to $0.19.